Martina McDermott, PhD

Dr. Martina McDermott researches novel biomarker driver strategies for small molecule drug development for cancers with a high unmet need. In addition, she explores mechanisms of resistance to targeted therapies.

McDermott MSJ, Conlon N, Browne BC, Szabo A, Synnott NC, O'Brien NA, Duffy MJ, Crown J, O'Donovan N. HER2-Targeted Tyrosine Kinase Inhibitors Cause Therapy-Induced-Senescence in Breast Cancer Cells. Cancers (Basel). 2019 Feb 8;11(2). pii: E197. doi: 10.3390/cancers11020197.

Welin ER, Ngamnithiporn A, Klatte M, Lapointe G, Pototschnig GM, McDermott MSJ, Conklin D, Gilmore CD, Tadross PM, Haley CK, Negoro K, Glibstrup E, Grunanger CU, Allan KM, Virgil SC, Slamon DJ, Stoltz BM. Concise total syntheses of (-)-jorunnamycin A and (-)-jorumycin enabled by asymmetric catalysis. Science. 2019 Jan 18;363(6424):270-275. doi: 10.1126/science.aav3421. Epub 2018 Dec 20.

Chen M, Liang J, Ji H, Yang Z, Altilia S, Hu B, Schronce A, McDermott MSJ, Schools GP, Lim CU, Oliver D, Shtutman MS, Lu T, Stark GR, Porter DC, Broude EV, Roninson IB. CDK8/19 Mediator kinases potentiate induction of transcription by NF-Kappa-B. Proc Natl Acad Sci U S A. 2017 Sep 19;114(38):10208-10213. doi: 10.1073/pnas.1710467114. Epub 2017 Aug 30.

McDermott MSJ, Canonici A, Ivers L, Browne BC, Madden SF, O'Brien NA, Crown J, O'Donovan N. Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells. Int J Oncol. 2017 Jun;50(6):2221-2228. doi: 10.3892/ijo.2017.3976. Epub 2017 Apr 26.

McDermott MS, Chumanevich AA, Lim CU, Liang J, Chen M, Altilia S, Oliver D, Rae JM, Shtutman M, Kiaris H, Gyorffy B, Roninson IB, Broude EV. Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer. Oncotarget. 2017 Feb 21;8(8):12558-12575. doi: 10.18632/oncotarget.14894.